Zenas Biopharma Inc ZBIO.OQ ZBIO.O is expected to show a rise in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
The Waltham Massachusetts-based company is expected to report a 666.7% increase in revenue to $38.333 million from $5 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Zenas Biopharma Inc is for a loss of $1.03 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Zenas Biopharma Inc is $44.50, about 76.2% above its last closing price of $25.26
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -1.02 | -1.05 | -1.22 | Missed | -16.4 |
Jun. 30 2025 | -1.06 | -1.05 | -1.25 | Missed | -19 |
Mar. 31 2025 | -1.11 | -1.11 | -0.80 | Beat | 27.9 |
Dec. 31 2024 | -0.99 | -1.00 | -3.99 | Missed | -298.6 |
Sep. 30 2024 | -8.96 | -9.33 | -5.02 | Beat | 46.2 |
|
This summary was machine generated March 6 at 11:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments